Your shopping cart is currently empty

Avibactam free acid is a potent β-lactamase inhibitor exhibiting covalent and reversible properties, capable of inhibiting TEM-1, P99, and CTX-M-15 at nanomolar concentrations. Avibactam free acid and Ceftazidime may be combined for treating urinary tract infections.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $36 | - | In Stock | |
| 5 mg | $58 | - | In Stock | |
| 10 mg | $78 | - | In Stock | |
| 25 mg | $98 | - | In Stock | |
| 50 mg | $127 | - | In Stock | |
| 100 mg | $187 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $64 | - | In Stock |
| Description | Avibactam free acid is a potent β-lactamase inhibitor exhibiting covalent and reversible properties, capable of inhibiting TEM-1, P99, and CTX-M-15 at nanomolar concentrations. Avibactam free acid and Ceftazidime may be combined for treating urinary tract infections. |
| Targets&IC50 | TEM1:8 nM, CTX-M-15:5 nM |
| In vitro | Using TEM-1 as the research subject, the inhibitory effect of Avibactam free acid was characterized by measuring the on-rate (acylation) and off-rate (deacylation) of the enzyme. The results showed that the deacylation dissociation rate was 0.045 min⁻¹, providing potential insights into the deacylation pathway of TEM-1 enzyme. Using nuclear magnetic resonance (NMR) and mass spectrometry (MS), we discovered that the deacylation process regenerates intact Avibactam free acid rather than proceeding via hydrolysis [1]. |
| In vivo | In the mouse model infected with Klebsiella pneumoniae strain Y8, Ceftazidime-Avibactam free acid (0.375 mg/g, subcutaneous injection, every 8 hours for 10 days) exhibited significant antibacterial effects and produced certain therapeutic outcomes [3]. In the neutropenic pneumonia mouse model with Pseudomonas aeruginosa infection, following a single subcutaneous injection of Avibactam free acid (64 mg/kg), the mean estimated terminal-phase half-life in mouse plasma was 0.24 hours [3]. |
| Synonyms | NXL104 free acid |
| Molecular Weight | 265.24 |
| Formula | C7H11N3O6S |
| Cas No. | 1192500-31-4 |
| Smiles | [H][C@]12CN([C@@H](CC1)C(N)=O)C(=O)N2OS(O)(=O)=O |
| Relative Density. | 1.85 g/cm3 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (377.02 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (12.44 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.